EGFR, epidermal growth factor receptor, 1956

N. diseases: 1394; N. variants: 183
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 GeneticVariation group BEFREE Presently, the single nucleotide polymorphisms (SNPs) of EGFR/PLCE1 genes and their associations with EC survival remain unclear. 31209807 2019
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 Biomarker group BEFREE Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor (EGFR), the efficacy of nimotuzumab added to nCRT for esophageal cancer is uncertain. 31258850 2019
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 AlteredExpression group BEFREE Results indicated that PT shows more effective antitumor activity as compared with Pan both on EGFR-overexpressed KYSE-450 and KYSE-150 esophageal cancer cells, especially on KYSE-450 cells. 30596104 2018
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 Biomarker group BEFREE These phase 3 trial results point to little benefit to current EGFR-targeted agents in an unselected patient population, and highlight the need for predictive biomarkers in the treatment of esophageal cancer. 28687830 2017
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 Biomarker group BEFREE Results of this study suggest that anti-EGFR therapies should be investigated in prospective clinical trials in different settings in EGFR FISH-positive and, in particular, EGFR-amplified esophageal cancer. 28537764 2017
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 Biomarker group BEFREE A ligand-based and enediyne-energized bispecific fusion protein targeting epidermal growth factor receptor and insulin-like growth factor-1 receptor shows potent antitumor efficacy against esophageal cancer. 28498434 2017
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 AlteredExpression group BEFREE In this study, we first evaluated EGFR gene and protein expression in 70 Chinese EC patient tumor samples collected during surgery. 28881608 2017
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 Biomarker group BEFREE These results indicated that miR-133a could inhibit the MEK/ERK pathway to promote cell apoptosis and enhance radio-sensitivity by targeting EGFR in EC.. 27933650 2017
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 AlteredExpression group BEFREE We also observed a significant increase in ERCC1 expression, and decrease in p53 and EGFR expression, in EC-9706 cells treated with SNX-2112 (P < 0.05), indicating the regulation of EC by SNX-2112. 27420968 2016
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 AlteredExpression group BEFREE Real-time quantitative polymerase chain reaction technology (RT-PCR) was used to detect the expression of VEGF, HER-2, and EGFR mRNA in esophageal squamous cancer tissue of 60 cases and 30 cases of VEGF, HER-2, and EGFR mRNA in esophageal cancer adjacent tissues, and analyze its relationship with clinicopathological features. 26099724 2015
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 AlteredExpression group BEFREE Both YAP1 and EGFR are overexpressed in resistant esophageal cancer tissues compared with sensitive esophageal cancer tissues. 25739674 2015
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 Biomarker group BEFREE Expression and prognostic influence of NF-κB and EGFR in esophageal cancer. 26681028 2015
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 GeneticVariation group BEFREE EGFR intron-1 CA repeat polymorphism is a predictor of relapse and survival in complete resected only surgically treated esophageal cancer. 23377570 2014
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 Biomarker group BEFREE More than 50% EGFR-positive EsC and MPM cells were resistant to EGFR-TKI, and susceptibility to EGFR-TKI growth-inhibitory effect correlated positively with expression of E-cadherin (epithelial gene marker) and negatively with mesenchymal gene markers. 23749888 2013
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 Biomarker group BEFREE Epidermal growth factor receptor (EGFR), found in the epithelium of the digestive tract, plays an important role in epithelial repair and shows increased expression in different neoplasms, including esophageal tumors. 22875307 2013
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 Biomarker group BEFREE We evaluated the antitumor effects of lapatinib, a dual tyrosine kinase inhibitor which simultaneously inhibits EGFR and HER2, 5-fluorouracil (5-Fu) alone and in combination on esophageal cancer cells. 22293713 2012
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 AlteredExpression group BEFREE Over-expression of epidermal growth factor receptor in esophageal cancer is associated with poor prognosis. 22555809 2012
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 AlteredExpression group BEFREE In this report, the effect of PYM on EGFR expression in human esophageal cancer cells and the therapeutic efficacy of the combination of PYM and cetuximab on esophageal cancer xenograft were investigated. 22311160 2012
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 AlteredExpression group BEFREE We report the outcome in a series of esophageal cancer patients treated at our center and the results of a retrospective analysis of epidermal growth factor receptor (EGFR) expression and EGFR/HER2 gene copy numbers taken as possible prognostic and predictive factors. 23052161 2012
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 Biomarker group BEFREE Lapatinib inhibits receptor phosphorylation and cell growth and enhances antibody-dependent cellular cytotoxicity of EGFR- and HER2-overexpressing esophageal cancer cell lines. 21207425 2011
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 GeneticVariation group BEFREE The EGFR CA repeat genetic polymorphism may act as a valuable molecular predictor of clinical outcome of esophageal cancer after CCRT and esophagectomy, especially in those with good response to CCRT. 21298351 2011
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 Biomarker group CTD_human Targeting the human EGFR family in esophagogastric cancer. 21468131 2011
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 Biomarker group CTD_human MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. 22042947 2011
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 Biomarker group CTD_human The EGFR CA repeat genetic polymorphism may act as a valuable molecular predictor of clinical outcome of esophageal cancer after CCRT and esophagectomy, especially in those with good response to CCRT. 21298351 2011
CUI: C0014859
Disease: Esophageal Neoplasms
Esophageal Neoplasms
0.600 GeneticVariation group BEFREE Gene-gene interaction of EGFR 497Arg>Lys and EGF +61A>G polymorphisms enhanced risk for EC, indicating additive effects. 18773861 2008